Phenotypic Detection and Antimicrobial Profile of Metallo-Beta-Lactamase Producing *Pseudomonas aeruginosa* from Gunshot Wounds of In-Patients in Tertiary Hospitals in Maiduguri, Nigeria

Tijani Isa¹*, Ibrahim Yusuf Ngoshe¹, Khadija Abdulkarim Ma'aji¹, Amnon Jonathan¹, Adam Mustapha¹

Department of Microbiology, Faculty of Science, University of Maiduguri, Borno State, Nigeria¹

Background: *Pseudomonas aeruginosa* (*P. aeruginosa*) is the most common and significantly drug resistant bacteria isolated from all categories of in-patient wounds. The resistance is attributed to the production of metallo-B-lactamases (MBLs) responsible for high morbidity and mortality.

Methods: *P. aeruginosa* was isolated and identified from wound samples using Bergey's manual of systemic bacteriology. Each wound swab was used to inoculate MacConkey agar and Cetrimide agar. The ethylenediaminetetraacetic acid (EDTA) disk testing method and modified Kirby-Bauer disc diffusion method was conducted to determine the phenotypic characterization and antimicrobial profile of MBL-producing *P. aeruginosa*.

Results: Out of the 100 wound swabs examined, 24 (24.0%) of the isolates were identified as *P. aeruginosa*. Among the 24 isolates identified as *P. aeruginosa*, 8/24 (33.3%) of those isolates were MBL-producing. Male in-patients had a higher prevalence of 19 (79.2%) for *P. aeruginosa* than females with 5 (20.8%) (P< 0.05). MBL-producing *P. aeruginosa* was of a higher prevalence in males with 7 (87.5%) than in females with 1 (12.5%) (P<0.05). Based on wound location, the lower limbs had a higher prevalence of 18 (75%) than those on the upper limbs 3 (12.5%), head 2 (8.3%) and abdomen 1 (4.2%) (P<0.05) for *P. aeruginosa*. MBL-producing *P. aeruginosa* also had higher prevalence for wounds on the lower limbs 7 (87.5%) compared with those on the upper limb 1 (12.5%), head and abdomen each with 0(0%) (P<0.05). Antimicrobial profiles of *P. aeruginosa* isolates indicated a 100% resistance against cefepime 30 µg and ceftazidime 30 µg and highest level of susceptibility (20.8%) for meropenem 10 µg, imipenem 10 µg and gentamicin 10 µg. While all the MBL-producing *P. aeruginosa* isolates recorded a 100% resistance against all the antibiotics used.

Conclusion and Recommendation: These results demonstrate that spread as well as the rate of drug resistance among the MBL-producing *P. aeruginosa* is concerning. Imipenem and meropenem are potential drugs of choice for treatment of infections caused by MBL-producing *P. aeruginosa*.

Key words: Metallo-Beta-Lactamases, *Pseudomonas aeruginosa*, Gunshot-wounds, Inpatients, Antibiotic resistance, Maiduguri-Nigeria

Accepted: January 29, 2023

*Corresponding author: Tijani Isa. E-mail: tjelyakub@gmail.com

Introduction

Gunshot wounds are one of the most common cause of trauma worldwide and contribute significantly to economic burden, death and disability.^{1,2} The wound is usually contaminated with foreign materials such as bullets and thus, promotes pathogenic colonization and breakdown of defense mechanisms.^{3,4} The presence of colonizing microorganisms continue to provoke the immune system and interfere with normal process.⁵ Moreover, antibiotic healing resistance in wound pathogens reduces the efficacy of the antibiotic treatment protocol.⁴

Pseudomonas aeruginosa (P. aeruginosa) is regarded as the most common agent of wound infection especially in developing countries. ^{6,7,8,9} The organism is intrinsically resistant to multiple antibiotics including *B*-lactams (carbapenems), aminoglycosides, fluoroquinolones, and polymyxin B.^{10,11} The prevalence of carbapenem resistance has been increasingly reported in several countries.^{10,12}

In 2017, the World Health Organization (WHO) ranked carbapenem-resistant-P. aeruginosa as the second most critical-priority bacterium among 20 antimicrobial-resistant bacterial species.¹³ This resistance is attributed to the production of metallo-B-lactamases (MBLs) which cleave the amide bond of the Blactone ring, impermeability or loss of porin OprD, or increased expression of an efflux pump.^{14,15} MBL-mediated resistance has been responsible for high morbidity and mortality among in-patients worldwide.^{10,12,18,16,17,18} It is imperative to conduct the rapid detection of MBL-producing P. aeruginosa amongst gunshot in-patients in Maiduguri as an aid to management and empirical therapy.

Study area

The study was conducted at the University of Maiduguri Teaching Hospital and Nigeria Army 7 Division Medical Services and Hospital, Maiduguri Nigeria from February 2022 to June 2022. Maiduguri, the capital of Bono State in Nigeria, is located in North-Eastern Nigeria and lies within latitude 11.15°N and longitude 30.05° E in the sudano-sahelian savanna zone.¹⁹ The state has an area of 71.210sq km with the population of 4,151,193 according to National census conducted in 2006.²⁰

Methodology

Samples population, collection, and processing

A total of one hundred (male: 76 and female: 24) wound swabs were aseptically collected using convenience purposive sampling from gunshot in- patients at the University of Maiduguri Teaching Hospital and the Nigerian army 7 Division medical services and Hospital Maiduguri. The samples were presserved on ice for investigation at the department of microbiology laboratory, University of Maiduguri. Informed consent for each sample collected was obtained and included the age of the patient, gender, and wound location.

Isolation and identification of Pseudomonas aeruginosa

Isolation and identification of the bacteria was conducted as described in Bergey's manual of systemic bacteriology.²¹ Each wound swab was inoculated by spread plate on MacConkey agar and Cetrimide agar and incubated aerobically at 37°C for 24hrs. Isolates were identified using morphological and biochemical characteristics.²²

Phenotypic test for detection of MBLproducing Pseudomonas aeruginosa

The phenotypic detection of MBL-producing *P*. *aeruginosa* isolates was conducted by EDTA disk testing. An overnight culture of the isolates was prepared in 2 mL of Mueller-Hinton broth (MHB), with turbidity 0.5 McFarland Standard (which is approximately 10^8 CFU/ml). The bacterial suspension was streaked evenly onto a 150-mm-diameter plate containing Muller Hinton Agar (Oxoid Ltd., Basingstoke, Hampshire, England). Two disks of imipenem 10mg, one of which was impregnated with 5 µL of 0.5 EDTA (Sigma, USA) solution were placed 10 mm apart from edge to edge on the surface of the same Muller Hinton Agar plates for 24 hours of incubation at 37° C. A difference of \geq 7mm in diameter between the zones of inhibition for the EDTA impregnated imipenem disk and imipenem disk alone indicated the presence of MBL-producing *P. aeruginosa*.^{23,24}

Antimicrobial susceptibility profile

The antibiotic susceptibility profile of the P. aeruginosa and MBL-producing P. aeruginosa isolates was evaluated using the Kirby-Bauer disk diffusion method as recommended by the Clinical Laboratory Standard Institute (CSLI) guidelines.^{25,26} Bacterial suspensions were prepared in 2 mL of Mueller-Hinton broth (MHB), with turbidity 0.5 McFarland Standard (which is approximately 10⁸ CFU/ml). The bacterial suspension was streaked evenly onto a 150-mm-diameter plate containing Muller Hinton Agar (Oxoid Ltd., Basingstoke, Hampshire, England). The anti-biogram was determined by comparing the zone of inhibition with the CSLI interpretative chart using meropenem 10 μ g, imipenem 10 μ g, ceftazidime 30 μ g, cefepime 30 µg, gentamicin 10 µg and ciprofloxacin 5 µg.

Statistical analysis

Data obtained were presented as percentage prevalence and statistical significance was determined using the student "T" test to compare the prevalence of *P. aeruginosa* isolates and MBL-producing *P. aeruginosa* isolates from gunshot wounds of in-patients with respect to location of the wounds and gender of the patients. P -values equal to or less than 0.05 are regarded as significant.

Results and Discussion

β-lactams, including carbepenems are considered the most potent agents for treatment of infections caused by *P. aeruginosa*.²⁷ Resistance to MβL among *P. aeruginosa* is increasing and has been reported in several countries.^{28,29}

In this study, out of the total of one hundred (100) (male: 76 and female: 24) gunshot wound samples collected, a prevalence of 24 (24%) were recorded for *P. aeruginosa*. Of these, 8 (33.3%) were recorded as MBL-producing *P. aeruginosa* by imipenem-impregnated EDTA test. (Figures 1,2) However, the result revealed that male in-patients had a higher prevalence rate of 19 (79.2%) for *P. aeruginosa* than females with 5 (20.8%), while male had a




Figure 1. EDTA Disk Testing method showing enhanced inhibition zone of >7mm around IPM + EDTA disc indicating MBLs positivity.




Figure 2: Percentage prevalence of metallo-ß lactamase (MBL) producing *P. aeruginosa*

higher prevalence rate of 7(87.5%) for MBLproducing *P. aeruginosa* than females with 1(12.5%). (Figures 3, 4) Based on wound location, the lower limbs had a higher prevalence rate of 75% (18/24) for *P. aeruginosa* than the upper limbs 12.5% (3/24), head 8.3% (2/24) and abdomen 4.2% (1/24). (Figure 5) The lower limbs had a higher prevalence rate of 87.5% (7/8) for MBL-producing *P. aeruginosa* than the upper limb 12.5% (1/8), head 0% (0/8) and abdomen 0% (0/8). (Figure 6) The variation in the patient's gender and wound location in relation to the prevalence of *P. aeruginosa* and MBL-producing *P. aeruginosa* infection was statistically significant (P<0,05).





Figure 3: Percentage prevalence of *P. aeruginosa* based on gender of in-patients








Figure 5: Percentage prevalence of *P. aeruginosa* based on wound locations.





Figure 6: Percentage prevalence of metallo-ß lactamase producing *P. aruginosa* based on wound location.

Though, the prevalence rates in this study are low, MBLs among P. aeruginosa have been increasingly recognized from clinical isolates worldwide. Ettu et al. (2021) in Nigeria reported 81.5%; 37.6% in West of Iran, Hamadan by Arash et al., (2022); 35.1% in Egypt by Rehab et al., (2021); 34.2% in Ghana by Hayford et al., (2021); 18.95% in India by Kunachgi et al. (2015); 24.2% in Korea by Nam et al., (2010) and 15% in Nepal by Reshma et al. (2020).^{30,31,32,33,34,35,36} The findings in this study, however are substantially higher than the reports from Europe and other developed nations where infection rates of 2.3% (23/996) in 2004 and 2.1% (21/992) in 2006 across clinical specimens were reported in Japan.³⁷ In Italy and Spain, the MBL prevalence in P. aeruginosa was reported as 1.3% and 0.1% respectively.^{38,39}

The incidence of MBL-producing *P*. *aeruginosa* is due to intrinsic resistance of the organism,⁴⁰ and its associated risk factors, both of which led to spread of the bacteria. It has been emphasized that the detection of MBLs among *P*. *aeruginosa* is crucial for optimal treatment of patients due to the increase in B-lactam usage and emergence of resistant bacteria under antibiotic pressure.⁴¹

Figure 7 and 8 show the antimicrobial susceptibility profile of *P. aeruginosa* isolates and MBL-producing *P. aeruginosa* isolates denoting the resistance, intermediate and

susceptibility patterns. The P. aeruginosa isolates demonstrated a 100% resistance to cefepime 30 µg and ceftazidime 30 µg, while the highest susceptibility was 20.8% each for meropenem 10 µg, imipenem 10 µg, and gentamicin 10 µg. This result indicates that the resistance levels were high across all the antibiotics tested. Such resistance has been previously reported and are due to the coexistence of genes encoding drug resistance to other antibiotics on the plasmids the isolates are harboring.^{42.} However, because of the very low permeability of the cell wall, P. aeruginosa is naturally resistant to B-lactams including broad spectrum cephalosporins and auinolones. 43, 44, 45





All eight (8) of the MBL-producing *P*. *aeruginosa* isolates recorded a 100% resistance against all the antibiotics examined in this study. A particularly important feature is that the MBL producers were resistant to all the Blactam antibiotics and the non-B-lactam antibiotics. This however indicates the multidrug resistant attribute of MBL-producing *P*. *aeruginosa* isolates and supports the claim that these 'superbugs' are minimally susceptible to empirical therapy.⁴¹ This was comparable to reports from other parts of the world, which




Figure 8: Antimicrobial profile of the metallo-B lactamase producing *P. aeruginosa* isolates to B-lactam antibiotics and other non-B-lactam antibiotics

also revealed multiple drug resistance among P. aeruginosa and the limited treatment options for wounds.¹⁴ Moreover, there are reports of growing concern of the MBL-producing P. aeruginosa showing cross resistance to non-B-lactam antibiotics.⁴⁶ Kateete et al. and Horieh et al. reported that resistance in P. aeruginosa was mainly due to the production of MBLs and other factors such as genetic mutations in over expression of the ampC gene, increased expression of the efflux pumps, decreased expression of proteins, impermeability through alteration or loss of the porin OprD, reduced outer membrane permeability, alteration in the target sites of antibiotics and less possibly involved are the increased activity of chromosomal cephalosporinases.^{15,41}

This study also demonstrated significant differences in the susceptibility profiles between MBL-producing and non MBL-producing *P. aeruginosa* for meropenem, imipenem and gentamicin, except for ceftazidime, cefepime and ciprofloxacin where no significant differrence was observed in the susceptibility patterns of both organisms. This indicates that MBL-producing strains of *P. aeruginosa* are

more likely to have low susceptibility to non Blactam antibiotics compared with non MBLproducing isolates of *P. aeruginosa*. In this regard, the hospitals should formulate an effective antibiotic policy.

Limitations

In this study, the great proportion of the population are male in- patients. All patients were determined to have wound infections resulting from the gunshot injuries during counter-insurgency/counter-terrorism

operations in Bono State, Nigeria. Hence, lack of a comparison group is a definite limitation of the study. Clinical details of patients such as history of antibiotic use are not included due to insufficient information. Also, molecular epidemiologic analysis and characterization to determine the MBL types and resistant genes were not carried out due to funding constraint.

Conclusion

This study revealed the presence and prevalence of MBLs in *P. aeruginosa* of gunshot wound patients. The isolates showed >60% resistance to B-lactam antibiotics including carbapenems and cephems and other non-B-lactam antibiotics, including gentamicin and ciprofloxacin. This high level of resistance may put the afflicted patient at an increased risk of

References

1. Prat NJ, Daban JL, Voiglio EJ, et al. Wound ballistics and blast injuries. J Visc Surg 2017; 154: 9-12. DOI:

10.1016/j.jviscsurg.2017.07.005.

2. Ugurlar M, Fatih K, Mesut MS, et al. The plate fixation in the treatment of complex forearm open fractures. Hand Microsurg 2017; 6: 1-8.

DOI:10.5455/handmicrosurg.16394

3. Papasoulis E, Michael JP, Charalampos GZ. Antibiotics in the treatment of lowvelocity gunshot-induced fractures: a systematic literature review. Clin Orthop Relat Res 2013; 471: 3937-3944. DOI 10.1007/s11999-013-2884-z developing a multidrug resistant infection. However, accurate identification and reporting of MBL-producing *P. aeruginosa* will aid in limiting the spread of the organism.

Acknowledgements

The authors would like to thank the management and staff of University of Maiduguri Teaching Hospital and Nigeria Army 7 Division Medical Services and Hospital, Maiduguri Nigeria, more especially staff in orthopedic clinic/ ward of the hospitals. The authors also wish to thank the Head of Department, Head of Laboratory and staff Veterinary Microbiology, Faculty of Veterinary Medicine, University of Maiduguri, Nigeria for their technical support during this research study.

Ethical Approval

The study was approved by the Research Ethics Committee of the University of Maiduguri Teaching Hospital Maiduguri, Nigeria and Nigeria Army 7 Division Medical Services and Hospital, Maiduguri Nigeria (decision number: UMTH/REC/21/949 and 7 DMSH/G1/300/26 respectively).

Informed Consent

The written informed consent was obtained from the study participants.

4. Steven LP. and Sara MM. Silver and Alginates: Role in Wound Healing and Biofilm Control. Advances in Wound Care 2014; 4: 7. DOI: 10.1089/wound.2014.0541

5. Hart J. Inflammation. 2: Its role in the healing of chronic wounds. J Wound Care 2002; 11: 245-249. DOI:

10.12968/jowc.2002.11.7.26416

6. Nagwa MA, Sanaa MS, Sahar IN, Yasmeen AA. Evaluation of antimicrobial activity of some plant extracts against antibiotic susceptible and resistant bacterial strains causing wound infection. Bulletin of the National Research Centre 2019; 43: 144.

7. Aljanaby AAJ, Aljanaby IAJ. Prevalence of aerobic pathogenic bacteria isolated from patients with burn infection and their antimicrobial susceptibility patterns in Al-Najaf City, Iraq- a three-year crosssectional study. F1000Research 2018; 7:1157

8. Pallavali RR, Degati VL, Lomada D, et al. Isolation and in vitro evaluation of bacteriophages against MDR bacterial isolates from septic wound infections. PLoS ONE 2017; 12: 179-245

9. Lundy AE, Patrycja R, Katarzyna S, et al. Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. Plos One. 2017; 10:1371.

10. Mirzaei B, Bazgir ZN, Goli HR, et al. "Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from northeast of Iran," BMC Research Notes 2020; 13: 380-2020, 2020.

Potron A, Poirel L, Nordmann P.
 Emerging broad-spectrum resistance in
 Pseudomonas aeruginosa and Acinetobacter
 baumannii: mechanisms and epidemiology.
 Int. J. Antimicrob. Agents 2015; 45: 568-585.

12. Hong DJ, Bae IK , Jang IH, Jeong SH, Kang H K, Lee K. Epidemiology and Characteristics of Metallo-B-Lactamase-Producing Pseudomonas aeruginosa. Infect Chemother 2015; 47: 81-97

13. Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet. Infectious diseases 2018; 18: 318-327.

14. Tahmasebi H, Maleki F, Dehbashi S, et al. "Role and function of KPC and MBL enzymes in increasing the pathogenicity of Pseudomonas aeruginosa isolated from burn wounds," Journal of Babol University of Medical Sciences 2019; 21: 127-134.

15. Kateete DP, Nakanjako R, Namugenyi J, et al. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at

Mulago Hospital in Kampala, Uganda (2007-2009). Springerplus 2016; 5: 1308.

16. Khan AU, Mar yam L, Zarrilli R.
Structure, Genetics and Worldwide Spread of New Delhi Metallo-B-lactamase (NDM): a threat to public health. Microbiol 2017; 17: 101.

17. Kaleem F, et al. Frequency and susceptibility pattern of metallo-betal actamase producers in a hospital in Pakistan.J Infect Dev. Ctries 2010; 4: 1050.

 Persoon MC, Holt AF, Bokhoven KC, et al. Mortality related to Verona Integronencoded Metallo-B-lactamase-positive Pseudomonas aeruginosa: Assessment by a novel clinical tool. Antimicrob Resist Infect Control 2019; 8: 1.

 Udo RK. "A Comprehensive Geography of West Africa". (1st edition). Heinemann Educational Books Nig. Ltd., 1978.

20. Report of Nigeria's National
Population Commission on the 2006 Census
Population and Development Review.
Published By: Population Council 2017;
33:206-210

https://www.jstor.org/stable/25434601/ 21. Michael G, Peter K, Hans-Jürgen B, et al. Bergey's manual of systematic bacteriology. Second edition, Volume five. Springer New York Dordrecht Heidelberg London 2012; DOI 10.1007/978-0-387-68233-4, ISBN 978-0-387-95043-3, ISBN 978-0-387-68233-4 (eBook)

22. Cowon ST, Steel KJ. Manual for the identification of medical bacteria (2nd Edition). Cambridge University Press 2002; P. 51-60.

23. Pitout JDD, Gregson DB, Poirel L, et al. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43: 3129-3135.

24. Sachdeva R, Sharma B, Sharma R. Evaluation of different phenotypic tests for detection of metallo-B-lactamases in imipenem-resistant Pseudomonas aeruginosa. Journal of laboratory physicians. 2017; 9:249. Bauer AW, Kirby, WM, Sherris JC, et al. Antibiotic susceptibility testing by a standard single disc method. American Journal Clinical Pathology 1966; 45: 493-496.
 Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Approved standard-31st edition, CLSI supplement M100, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne Pennsylvania, USA. 2021; 2B-1.

 Mathur P, Behera B, Sharma V, et al.
 An evaluation of four different phenotypic techniques to evaluate detection of Metallo β-lactamases. Indian Journal of Medical Research 2008; 45: 140-145.

28. Zilberberg, MD, Chen J, Mody SH, et al. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. Pulm. Med. 2010; 10: 45. DOI: 10.1186/1471-2466-10-45

29. Kotgire SA, Tankhiwale N. Prevalence and Antimicrobial Susceptibility Profile of Metallo-B-Lactamases (MBL) Producing Pseudomonas areuginosa from Rural Hospital: Comparison of Two Disk Diffusion Methods. International Journal of Basic and Applied Medical Sciences 2011; 1: 13-17, ISSN: 2277-2103 (Online) An Online International Journal Available at

http://www.cibtech.org/jms.htm 30. Ettu AO, Oladapo BA, Oduyebo O. Prevalence of carbapenemase production in Pseudomonas aeruginosa isolates causing clinical infections in Lagos University Teaching Hospital, Nigeria. Afr. J. Clin. Exper. Microbiol 2021; 22: 498-503, https://dx. DOI.org/10.4314/ajcem.v22i4.10 31. Arash S, Sanaz D, Hamed T, et al. Detection of blaOXA-145, blaOXA-224, blaOXA-539, and blaOXA-675 Genes and Carbapenem-Hydrolyzing Class D-Lactamases (CHDLs) in Clinical Isolates of Pseudomonas aeruginosa Collected from West of Iran, Hamadan. International Journal of Microbiology 2022, Article ID 3841161, 10 pages https://DOI.org/10.1155/2022/3841161 32. Hayford O, Vivian EB, Yaw Duah B, et al. Prevalence and Phenotypic and Genotypic Resistance Mechanisms of Multidrug-Resistant Pseudomonas aeruginosa Strains Isolated from Clinical, Environmental, and Poultry Litter Samples from the Ashanti Region of Ghana. Hindawi Journal of Environmental and Public Health 2021; Article ID 9976064, 12 pages https://DOI.org/10.1155/2021/9976064

 Rehab M, Magdy FE, Asmaa A, et al.
 Identification and Characterization of Metallo-B-Lactamases Producing Pseudomonas aeruginosa Clinical Isolates in Al-Azher University Hospital, Assiut. Bull. Pharm. Sci., Assiut University 2021; 44: 161-172.

34. Kunachgi PN, Syed SR, Hima BM, et al.
Antibiotic sensitivity pattern and imipenem-EDTA double disk synergy test for the detection of Metallo-beta-lactamase producing Pseudomonas aeruginosa from clinical samples in a teaching hospital. Int. J.
Curr. Microbiol. App. Sci 2015; 4: 866-871
35. Nam HR, Jung SH, Dong SJ, et al.

Prevalence of Metallo-B-lactamases in Imipenem-nonsusceptible Pseudomonas aeruginosa and Acinetobacter baumannii. Korean J Clin Microbiol 2010; 13: 169.

36. Reshma M, Basudha S, Sanjit S, et al. Detection of Metallo-B-Lactamases and Carbapenemase Producing Pseudomonas aeruginosa Isolates from Burn Wound Infection. TUJM 2020; 7: 67-74.

37. Yoko M, Tomoo S, Yoshikazu I, et al.
Molecular analysis of the integrons of metallo-B-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan.
Microbiology 2015; 15: 41. DOI 10.1186/s12866-015-0378-8

38. Gutiérrez O, Juan C, Cercenado E, et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrobial Agents and Chemotherapy 2007; 51: 4329-4335. 39. Rossolini GM, Luzzaro F, Migliavacca R, et al. First countrywide survey of acquired metallo-8-lactamases in gram-negative pathogens in Italy. Antimicrobial Agents and Chemotherapy 2008; 52: 4023-4029.

40. Yassin NA, Khalid HM, Hassan AO. Prevalence of Metallo-B-Lactamase producing Pseudomonas aeruginosa in wound infections in Duhok city, Iraq. IMSEAR 2014; ID: sea-165499.

41. Horieh S, Hosein L, Parviz O, et al. Detection of Metallo-B-Lactamase Producing Pseudomonas aeruginosa Isolated From Burn Patients in Tehran, Iran. Labmedicine 2010; 41:10.

42. Bartlett, J. G. 2004 Pocket Book of Infectious Disease Therapy. Baltimore: Lippincott Williams & Wilkins 2004.

43. Drlica K, Hiasa H, Kerns R, et al. Quinolones: action and resistance updated. Curr. Top. Med. Chem 2009; 9: 981-998. 44. Paul M, Yahav D, Bivas A, et al. Antipseudomonal B-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of B-lactams. Cochrane Database Syst. Rev 2010; 11: CD005197

45. Varun G, Sumati A, Hogade SG, et al. Prevalence of extended-spectrum betalactamases, AmpC beta-lactamase, and metallo-beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii in an intensive care unit in A tertiary Care Hospital. Journal of the Scientific Society 2013; 40: 1.

46. Hansi K, Deepak B, Diansy Z, et al. Role of Pseudomonas aeruginosa AmpR on blactam and non-b-lactam transient crossresistance upon pre-exposure to subinhibitory concentrations of antibiotics. Journal of Medical Microbiology 2014; 63: 544-555 DOI 10.1099/jmm.0.070185-0



GUARDIANS OF QUALITY AND PATIENT SAFETY: BIOMEDICAL LABORATORY SCIENTISTS INTERNATIONAL BIOMEDICAL LABORATORY SCIENCE DAY - APRIL 15TH 2023



International Federation of Biomedical Laboratory Science

IFBLS.org